Voriconazole does not affect the steady-state pharmacokinetics of digoxin

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 45-50

  Purkins, Lynn ^a   Wood, Nolan ^a   Kleinermans, Diane ^b   Nichols, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Cytochrome P450; Digoxin; Pharmacokinetics; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; DIGOXIN; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; EYE PAIN; FUNGICIDAL ACTIVITY; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VISUAL DISORDER;

EID: 0344512413     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01998.x     Document Type: Article

References (31)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
7. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182.
8. Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F78, September 1995.
9. Patterson BE, Roffey S, Jezequel SG, Jones B. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Abstract F79, September 1995.
10. Alderman CP, Allcroft PD. Digoxin-itraconazole interaction: possible mechanisms. Ann Pharmacother 1997; 31: 438-440.
11. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 227-244.
12. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol 1998; 40: 45-46.
13. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol 1985; 5 (Suppl A): 82A-90A.
14. Cone LA, Himelman RB, Hirschberg JN, Hutcheson JW. Itraconazole-related amaurosis and vomiting due to digoxin toxicity. West J Med 1996; 165: 322.
15. Meyboom RH, de Jonge K, Veentjer H et al. Potentiation of digoxin by itraconazole. Ned Tijdschr Geneeskd 1994; 138: 2353-2356.
16. McClean KL, Sheehan GJ. Interaction between itraconazole and digoxin. Clin Infect Dis 1994; 18: 259-260.
17. Alderman CP, Jersmann HP. Digoxin-itraconazole interaction. Med J Aust 1993; 159: 838-839.
18. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993; 16; 400-403.
19. Kauffman CA, Bagnasco FA. Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992; 15: 886-887.
20. Albengres E,Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Safety 1998; 18: 83-97.
21. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-613.
22. Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996; 79: 274-276.
23. Salphati L, Benet LZ. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998; 56: 308-313.
24. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996; 24: 142-147.
25. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
26. SAS/STAT User's Guide, Version 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
27. Kim RB, Wandel C, Leake B et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-414.
28. Hartmann M, Huber R, Bliesath H et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 1995; 33: 481-485.
29. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 3944-3948.
30. Nishihara K, Hibino J, Kotaki H, Sawada Y, Iga T. Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. Biopharm Drug Dispos 1999; 20: 145-149.
31. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.